IL17A and lung cancer: Interleukin-3, 4, 13 and 17 (IL-3, IL-4, IL-13, IL-17) signaling pathways, p53 signaling, oxidative damage response, and SUMOylation are involved in the development of lung cancer (Suppl Fig. 2 & Suppl Table 5) but not breast cancer.